首页> 外文期刊>JAMA: the Journal of the American Medical Association >Idiopathic intracranial hypertension - Reply
【24h】

Idiopathic intracranial hypertension - Reply

机译:特发性颅内高压-回复

获取原文
获取原文并翻译 | 示例
       

摘要

In Reply We stand by our statement that there were no properly designed and executed clinical trials to guide therapy in IIH prior to ours. The results of the study by Ball et al1 were inconclusive with respect to efficacy due to the small sample size and consequent low power. The authors stated in their report that "This pilot study was not powered to detect a treatment effect."1 Also, 12 of 25 patients in the acetazolamide group stopped taking medication, a discontinuation rate of nearly 50%. Dosing schedules for acetazolamide were at the discretion of the supervising clinician and did not get above 1500 mg/d. Twenty percent of the patients in the control group were eventually given acetazolamide. Therefore, this trial should not be used to guide therapy in IIH.
机译:在答复中,我们支持我们的声明,即在我们之前,没有适当设计和执行的临床试验来指导IIH治疗。 Ball等人[1]的研究结果由于样本量小和功效低而没有定论。作者在报告中指出:“这项先导研究无权检测治疗效果。” 1此外,乙酰唑胺组的25名患者中有12名停止服药,停药率接近50%。乙酰唑胺的给药方案由临床医师酌情决定,剂量不超过1500 mg / d。对照组中有20%的患者最终接受了乙酰唑胺。因此,该试验不应用于指导IIH治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号